BioCentury
ARTICLE | Clinical News

Zafgen rises on more beloranib data

March 10, 2015 2:17 AM UTC

Zafgen Inc. (NASDAQ:ZFGN) gained $3.05 to $41.80 on Monday after reporting full results from a Phase II trial in which beloranib led to weight loss in adults with hypothalamic injury associated obesity (HIAO) without required adherence to diet or exercise regimens, with no waning of effects after eight weeks of treatment.

Beloranib led to a mean weight loss of 3.4 kg at four weeks vs. 0.3 kg with placebo (p=0.01), the trial's primary endpoint. During a four-week open-label extension, patients initially randomized to receive beloranib continued to lose weight and had a mean loss of 6.2 kg by week eight. Patients who switched over from placebo had a 3.2 kg loss at eight weeks. HIAO is a rare condition resulting from damage to the hypothalamus following resection of CNS tumors. ...